BLLN Overview

BillionToOne, Inc. is a precision diagnostics company that quantifies biology to create molecular diagnostics. The Company's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. It applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.

Wall Street analysts forecast BLLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLLN is137.83 USD with a low forecast of 110.00 USD and a high forecast of 160.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

BillionToOne Inc revenue for the last quarter amounts to 96.05M USD, decreased

BillionToOne Inc. EPS for the last quarter amounts to 0.04 USD, decreased

BillionToOne Inc (BLLN) has 713 emplpoyees as of April 01 2026.

Today BLLN has the market capitalization of 3.19B USD.